# Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic (Video)

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-us-rollout-begins-as-lung-cancer-test-moves-from-lab-to-clinic-video/4121218382
- Published: 2025-09-30T07:34:53+01:00
- Author: Ethan Davis

**Cizzle Biotechnology Holdings PLC** (LON:CIZ), the UK based healthcare diagnostics
developer, has announced its interim results for the six months ended 30 June 2025.
DirectorsTalk caught up with Executive Chairman Dr Allan Syms to discuss the news.

**Key Moments**

00:12 — Mission reminder: tackling the 5,000 daily lung cancer deaths

02:03 — Transition from research to commercialisation

02:52 — Cizzle Bio’s North American validation strategy

03:13 — New partner: OmniHealth signs on for nationwide rollout

04:17 — Clinical lab expansion and Cayman Islands contract

05:34 — Upfront royalties and funding updates

06:07 — US clinical partnerships explained

08:53 — Collaboration with Moffitt Cancer Center

12:07 — What’s next: six-month roadmap and UK/EU expansion

**Interim Highlights**

·    **January 2025:** **Professor Dawn Coverley, Founder and Non-Executive Director
was appointed Chief Scientific Officer.** This followed the completion of major 
research and development milestones for the CIZ1B Biomarker test, and to facilitate
support to the Company’s global licensing partners as they enter the commercialisation
phase.

·    **January 2025: Research Agreement extension:** The Group’s research agreement
with the University of York was extended until 28 June 2026.

·      **March 2025**: **Pathfinder lab appointed**: Cizzle’s North America Licensing
Partner, Cizzle Bio Inc (“BIO”) appointed its first pathfinder laboratory.

·      **March 2025:** **Board appointment:** Matt Bower was appointed as a Non-
Executive Director to strengthen the Board by adding his experience in advising 
and mentoring high technology businesses globally, to enhance corporate governance
and replace Professor Coverley on the Audit and Remuneration Committees.

·      **April 2025:** **Hospital contract secured:** BIO executed its first contract
in the Caribbean as part of the extension to its exclusive licensing and partnership
agreement with the Company for the USA and Canada with Doctors Hospital Cayman, 
triggering early royalty payments of which US$125,000 was received in July 2025.

·      **June 2025: Up-front fees and advanced royalty payments:** During the period
ended June 2025, the Company received US$400,000 of the agreed and guaranteed US
$2.4 million payments due. A further payment of US$125,000 in July 2025 meant that
the total receipts amounted to US$525,000.

·      **April 2025:** **New website**: The Company launched its new website to 
allow all stakeholders, shareholders, investors and customers to access a wide range
of information and latest news on the Company’s status and products.

·      **May 2025:** **Fund raise of** **£150,000:** Through the issue of a convertible
loan note to provide additional funding to support the Company’s growth strategy,
in particular to seek partnerships for its CIZ1B early cancer test in the UK and
elsewhere in Europe. The note was subscribed for by Frazer Lang, an existing investor
in the Company and is convertible at any time at a price of 1.4 pence per share.

·      **Financial results**: Loss for the period of £368,000 (H1 2024: loss of 
£1,411,000).

**Post Period Highlights**

·    **Commercial Launch**: In August 2025, following progress achieved at their
pathfinder lab, BIO realigned their accreditation and market launch strategy with
a new multi-site clinical laboratory, enabling a much wider co-ordinated and comprehensive
campaign to roll out the CIZ1B biomarker test in North America. Omni Health Diagnostics(“
Omni”) announced in September 2025 that the roll out programme will be nationwide
in at least six states with potential further expansion. This demonstrates how BIO
intends to scale its operations to meet expected demand in the USA. 

·    **Moffitt Cancer Center Collaboration**: On 9 September 2024, the Group was
selected by Moffitt Cancer Center (“Moffitt”), Florida’s leading cancer hospital,
to test patients with suspicious lung nodules in a clinical evaluation using the
Group’s proprietary CIZ1B biomarker assay. Since then, Moffitt has been recruiting
patients and collecting blood samples to ship to the University of York. We expect
samples to be received shortly and testing to begin in Q4 2025. This important study
to test patients for the presence of the CIZ1B Biomarker is part of a major clinical
evaluation for suspected lung cancer patients.

**Commenting Allan Syms, Chairman of Cizzle Biotechnology, said****:**

_“The first half of 2025 has been a period focussed on validation, accreditation
and building, together with our licensing partner Cizzle BIO in the USA, a comprehensive
base from which our simple blood test to help in the early detection of lung cancer
can be launched for commercial use. Enabled by the Company’s agreement with BBI 
Solutions (“BBI”), an established accredited supplier who now manufacture our antibodies
in their_ _ISO 13485-certified facilities__, BIO has completed its pathfinder programme
and entered into an agreement with Omni Health Diagnostics to launch the test across
the USA through multiple sites to meet expected demand. BIO have invested in significant
marketing and partnership campaigns to build awareness through a co-ordinated campaign
and are now poised for commercial launch. The accreditation process is underway 
at Omni, who expect to obtain CLIA accreditation and launch in the near future. 
The Company continues to receive payments from BIO as part of the advanced royalty
schedule, which demonstrates the close working relationship we have as we create
a platform to help detect lung cancer early. The Company is now expanding its licensing
activities elsewhere, including in the UK, and we look forward to updating our shareholders
with progress in due course.”_

**Executive Chairman’s Statement**

**_Operational and strategic overview_**

In Cancer Research UK’s report on ‘Early Detection and Diagnosis of Cancer: A Roadmap
to the Future’ *Professor Chris Whitty, Chief Medical Officer for England and Chief
Scientific Adviser for the Department of Health and Social Care said “_The early
detection and diagnosis of serious disease, including cancer, changes outcomes substantially.
If cancer can be intercepted at the earliest clinically relevant timepoint this 
gives a much better chance of survival and an improved quality of life.”_

With over 5,000 people daily losing their lives to lung cancer and the main reason
being the lack of early detection, the Group’s technology aims to eliminate barriers,
empowering patients and healthcare providers with a cutting-edge solution to one
of the greatest challenges in modern medicine. The Group’s vision is a global shift
in lung cancer survival through accurate, low cost, non-invasive early detection
at scale. The Group remains focussed on the systematic development and commercialisation
of novel and proprietary clinical diagnostic tests for the early detection of cancer
particularly where there is an unmet clinical need.

The Group’s platform technology is based on the ability to detect a stable plasma
biomarker, a variant of a normal protein, CIZ1, which is a naturally occurring cell
nuclear protein involved in DNA replication. The targeted CIZ1B variant is highly
correlated with early-stage lung cancer and since the Group’s admission to the London
Stock Exchange in 2021, it has invested in the development of its technology to 
enable its full commercialisation through a global licensing and partnership strategy.

With the commercial manufacture of CIZ1B monoclonal antibodies now established, 
and a guaranteed royalty stream being generated by our first licensing partner BIO
in North America and the Caribbean, and validation of the test in progress, it is
anticipated that commercial sales will begin in the near future followed by further
licensing and partnership deals elsewhere in the world.

_*https://assets.ctfassets.net/u7vsjnoopqo5/2Q32Uv00MxEAUS34Gw8WHk/68ee767b745332d8ce1daf81037807dc/
early\_detection\_diagnosis\_of\_cancer\_roadmap.pdf_

**_Research and Development Progress_**

Based on the original published research by Professor Coverley and her team at the
University of York, it has been shown that CIZ1B can be measured with high sensitivity
that should allow for non-intrusive, cost-effective testing in a high-throughput,
hospital-friendly format, and in the future a potential rapid point of care test
for use in doctors’ offices and pharmacies.  During the period, Cizzle continued
to support its research agreement and collaboration with the University of York 
which has been extended to 28 June 2026. The Group has reported the successful generation
and subsequent manufacture of its proprietary monoclonal antibodies by BBI, the 
world’s largest independent producer of immunodiagnostic reagents. Entry into production
of this central component of the Company’s test to detect the presence of the CIZ1B
biomarker, was an inflexion point in enabling the clinical validation process to
be undertaken.

Professor Coverley’s team have been instrumental in their support to BIO’s pathfinder
laboratory and to Omni Health Diagnostics in providing a Standard Operating Procedure(
SOP) which serves as an operational guide for the clinical laboratories that will
seek CLIA accreditation of the CIZ1B test as a LDT in North America. This ensures
uniformity in performance, quality control, and adherence to regulations, which 
reduces errors, improves safety, and preserves institutional knowledge within an
organisation and is essential in obtaining regulatory validation in the near term.

The Group announced on 9 September 2024 that it had been selected by the Moffitt
Cancer Center, the number one cancer hospital in Florida and the Southeast USA, 
to test patients with suspicious lung nodules in a clinical evaluation using the
Group’s proprietary CIZ1B biomarker assay. Since then, Moffitt has been recruiting
a large patient cohort and will send the first batch of blood samples to be tested
for the CIZ1B Biomarker at the University of York. As previously reported, this 
will for the first time be analysing patient blood samples to determine biomarker
accuracy in predicting whether or not a lung nodule is likely to be cancer as part
of a real-world clinical evaluation in a hospital setting.

**_Licensing Strategy and Commercial Progress_**

The Company continues to operate a global licensing and partnership strategy because
the directors believe this is the fastest and most cost-effective means to bring
its technology to market. For product solutions, an outsourcing approach has been
adopted which aims to leverage external partners expertise and to provide an effective
cost management process. As such the Group has benefited from its research and development
agreement with the University of York through access to skilled scientists and laboratory
facilities. It has also produced commercial antibodies through agreement with an
industry leading and iso 13485 accredited facility, and has secured its first royalty
bearing licensing agreement in North America and the Caribbean. The licensing approach
of up-front fees and guaranteed royalties has generated important revenue for the
Group, avoided the need to fund and build an expert team in the licensed territory
and as such accelerated market deployment and installation of laboratory testing
accreditation and testing capability.

BIO is now completing validation of the test with its new clinical diagnostics laboratory
group, Omni Health Diagnostics (“Omni”), as part of a national expansion strategy
based on Omni’s active laboratory acquisitions and partnerships programme to provide
testing capability in Texas, New York, California, South Carolina, Tennessee and
Florida which will provide nationwide testing coverage. It is expected that BIO 
will add further clinical laboratory partners as required to be able to meet anticipated
market demand across North America when the test completes Clinical Laboratory Improvement
Amendments (“CLIA”) accreditation as a Laboratory Developed Test (“LDT”).

The anticipated commercial launch of the Group’s CIZ1B test in the USA is expected
to be followed by the Group’s expansion into different geographies, and maximise
speed and scale of market entry through specialist licensing partners globally. 
The Group’s next focus will be in the UK and Europe.

**_Funding_**

During the period, the Group announced that it has raised £150,000 through the issue
of a convertible loan note (the “Note”), to provide additional funding to support
the Company’s growth strategy, in particular to seek partnerships for its CIZ1B 
early cancer test in the UK and elsewhere in Europe, following the successful licensing
agreement with BIO in North America. The Note, which was subscribed for by Frazer
Lang, an existing investor in the Company, is convertible at any time, at the election
of the Note holder, during its 24-month term into new ordinary shares in the Company
at a price of 1.4 pence per share. No interest is payable on the Note.

On 18 August 2025, the Company announced BIO’s appointment of a new multi-site full
scale COLA and CLIA accredited laboratory group (later announced as Omni) to launch
the Company’s CIZ1B biomarker test throughout the USA. As part of agreed advance
exclusivity and royalty fees, BIO paid an early payment of US$125,000 to the Company
bringing total receipts at that date of US$525,000 of the guaranteed advance payments
of US$2.4m. The Company and BIO have now agreed to a new regular payment schedule
that will result in all remaining advance royalties being received by the end of
2026.

**_Financial overview_**

During the six months ended 30 June 2025, the Company continued its focus on being
a healthcare diagnostics developer. The Group consists of Cizzle Biotechnology Holdings
PLC as the parent company with wholly owned subsidiaries, Cizzle Biotechnology Ltd(“
CBL”) and Cizzle Biotech Ltd (formerly Enfis Ltd). The current Group structure was
formed when the Company completed the acquisition of CBL on 14 May 2021 and was 
admitted to trading on the Main Market of the London Stock Exchange.

The financial results for the six months to 30 June 2025 are summarised as follows:

·    Other income and interest receivable: £1,000 (H1 2024: £79,000)

·    Corporate expenses, before exceptional items: £346,000 (H1 2024: £299,000).

·    Non-cash administrative expenses relating to:

o  share option charge: £10,000 (H1 2024: £120,000)

o  Net fair value loss on financial asset: £Nil (H1 2024: £1,081,000) (related to
a current asset investment in Conduit Pharmaceuticals Inc (“Conduit”), a NASDAQ 
listed company, that was sold in H1 2025 for a loss on sale of investment £26,000(
H1 2024: £Nil).

·    Taxation credit: £13,000 (H1 2024: £10,000)

·    Total comprehensive loss of £368,000 (H1 2024, Loss £1,411,000).

·    Loss per share 0.09p, (H1 2024, Loss of 0.37p).

·    Cash balances as at 30 June 2025: £182,000 (30 June 2024: £484,000).

**_Responsibility Statement_**

We confirm that to the best of our knowledge:

·    the interim financial statements have been prepared in accordance with International
Accounting Standards 34, Interim Financial Reporting;

·    give a true and fair view of the assets, liabilities, financial position and
loss of the Company;

·    the Interim report includes a fair review of the information required by DTR
4.2.7R of the Disclosure and Transparency Rules, being an indication of important
events that have occurred during the first six months of the financial year and 
their impact on the set of interim financial statements; and a description of the
principal risks and uncertainties for the remaining six months of the year; and

·    the Interim report includes a fair review of the information required by DTR
4.2.8R of the Disclosure and Transparency Rules, being the information required 
on related party transactions.

The interim report was approved by the Board of Directors and the above responsibility
statement was signed on its behalf by Allan Syms on 30 September 2025.

Share on:
